Company Filing History:
1 out of 77 
1 out of 780 Years Active: 2025
Title: Innovator in Gene Editing: Karen Vo
Introduction: Karen Vo, based in Cambridge, Massachusetts, has made significant contributions to the field of gene editing with her innovative approach to targeting transferrin. With one patent under her belt, Vo exemplifies the spirit of inventiveness that drives advancements in biotechnology.
Latest Patents: Karen Vo's patent, titled "Compositions and methods for gene editing by targeting transferrin," offers groundbreaking methodologies for modulating gene expression, specifically focusing on blood-clotting proteins such as Factor VIII (FVIII). This patent encompasses various compositions, methods, and systems that can be utilized in both ex vivo and in vivo genome editing to treat disorders like Hemophilia A.
Career Highlights: Throughout her career, Karen has gained valuable experience working with prominent biotechnology companies. Notably, she has contributed to the progress of gene editing technology while working at Crispr Therapeutics AG and Bayer Healthcare LLC. Her expertise in the field has cemented her reputation among her peers.
Collaborations: During her professional journey, Karen Vo has collaborated with other talented individuals, including coworker Alan Richard Brooks. These partnerships have enhanced her research capabilities and have led to the development of innovative solutions in genetic therapy.
Conclusion: As a pioneering inventor, Karen Vo continues to push the boundaries of gene editing technologies. Her work not only addresses critical health conditions but also exemplifies the transformative potential of biotechnology in improving the lives of individuals affected by genetic disorders. The impact of her contributions will be felt for years to come in the realms of medicine and genetics.